Retrospective Evaluation of Empiric Vancomycin Therapy for Infectious Workups in Relation to Methicillin-Resistant Staphylococcus aureus (MRSA) Risk Factors in the Neonatal Intensive Care Unit

回顾性评估新生儿重症监护病房中经验性万古霉素治疗与耐甲氧西林金黄色葡萄球菌(MRSA)风险因素相关的感染性疾病诊疗方案

阅读:1

Abstract

OBJECTIVES: This study evaluated empiric antibiotic prescribing patterns in relation to methicillin-resistant Staphylococcus aureus (MRSA) risk factors in infants with potential late-onset sepsis (LOS). Secondarily, this study evaluated rates of escalation and de-escalation from initial antibiotic choice in patients who received at least 5 days of therapy. METHODS: This was a retrospective study of infants admitted to the neonatal intensive care unit (NICU) from December 1, 2022, to May 31, 2023. Infants at least 3 days old who received antibiotics for an infectious workup were included. The prevalence of risk factors for MRSA, including low birth weight, prematurity, outborn status, length of stay, parenteral nutrition, presence of indwelling lines, and history of MRSA-positive blood culture or colonization, was compared between patients who received vancomycin empirically or an alternative agent. RESULTS: A total of 143 blood cultures were obtained from 95 patients who received antibiotics for an infectious workup during the study period. Group 1 received vancomycin and included 51 (36%) blood cultures. Group 2 received an alternative agent and included 92 (64%) blood cultures. Patients in group 1 had higher rates of every MRSA risk factor included in this study, except for patients who were outborn. Group 1 also averaged a higher total number of MRSA risk factors per patient than group 2 (4.88 vs 2.53; p < 0.001). CONCLUSION: This institution uses MRSA risk factors to determine empiric antimicrobial therapy in suspected LOS. Further studies are needed to determine the relationship between the studied risk factors and incidence of MRSA infection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。